請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38740
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林君榮(Chun-Jung Lin) | |
dc.contributor.author | Szu-Yu Yeh | en |
dc.contributor.author | 葉思妤 | zh_TW |
dc.date.accessioned | 2021-06-13T16:44:13Z | - |
dc.date.available | 2015-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-16 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38740 | - |
dc.description.abstract | 糖尿病 (diabetes) 是一種慢性代謝性疾病,會造成全身微循環的障礙,進而引起腎臟方面的病變。P-glycoprotein (P-gp) 大量存在於腎臟中,主要功能是排除其受質及藥物等異質體,與腎臟組織的保護有關。由本實驗室先前西方墨點法與組織免疫染色的結果顯示,不論在第一型糖尿病Non-obese diabetic (NOD) 母鼠或第二型糖尿病New Zealand obese (NZO) 公鼠的腎臟中,P-gp表現量皆明顯下降;因此本實驗將接續先前的實驗結果,探討糖尿病腎臟中P-gp表現下降之調控機制。
在本研究中,使用犬腎小管上皮細胞MDCK II,作為研究腎臟P-gp表現量之體外試驗模型。為探討糖尿病造成腎臟P-gp表現下降之可能的調控機制,MDCK II分別以IL-6、TNF-α、insulin及高濃度葡萄糖處理後,萃取細胞膜蛋白做西方墨點法試驗,觀察P-gp表現量變化的情形。並以定量即時聚合酶鏈鎖反應 (qRT-PCR) 測定P-gp mRNA 表現量。結果顯示,高濃度葡萄糖會誘導活性氧化物 (ROS) 之生成,同時造成P-gp表現顯著下降;而在細胞激素 (IL-6, TNF-α) 和胰島素環境下則未呈現顯著影響。另一方面,ROS也可以造成P-gp表現下降, 並可被抗氧化劑 N-acetylcysteine (NAC) 所抵消。在高濃度葡萄糖環境下給予細胞PKC inhibitor staurosporine (STS),可抑制高濃度葡萄糖所造成P-gp 表現下降之現象,顯示PKC 的活化參與高濃度葡萄糖對於P-gp的調控。以PKC agonist PMA處理後P-gp 表現下降,然而共同處理NAC 與 PMA後,PMA誘導之P-gp 表現下降並未被NAC反轉。此外,也藉由觀察細胞內細胞核受體PXR、CAR及內皮素 (Endothelin-1, ET) 與P-gp 調控之關連性。實驗結果發現在高濃度葡萄糖處理24小時後,細胞中 PXR及CAR的mRNA 表現量皆顯著上升。另一方面,在PKC agonist PMA環境下處理12小時後,細胞中 PXR及CAR的mRNA 表現量則下降,這些處理皆未造成蛋白質表現量的改變;RT-qPCR分析並未發現MDCK II 細胞上有內皮素受體 ETR-A / B mRNA 的表現 總結上述研究結果,在高濃度葡萄糖環境下P-gp的表現量是顯著下降的。顯示由葡萄糖調節異常所引起的高血糖 (hyperglycemia) 為糖尿病造成腎臟P-gp 表現下降之主要機轉;且其調控P-gp表現量的機轉與ROS之生成以及活化PKC路徑有關。PXR、CAR、ET以及ETR-A / B路徑並未在此調控中扮演角色。然而是否有其他調控因子參與其中仍需做更進一步的探討。 | zh_TW |
dc.description.abstract | Diabetes mellitus is a chronic metabolic disease and is related to various complications including nephropathy. Diabetic nephropathy is the most common cause of end-stage renal disease. P-glycoprotein (P-gp) is abundant in the kidney and is closely related to the excretion of xenobiotics and drugs. In this regard, P-gp represents a protective mechanism to exclude endogenous and exogenous toxins in the kidney. Our previous study has shown that P-gp expression is significantly lower in the kidney of animals with type 1 diabetes (Non-obese diabetic, NOD females) or type 2 diabetes (New Zealand obese, NZO males). The present study is to investigate the underlying mechanisms regulating P-gp expression in the kidney under diabetic condition
Madin-Darby canine kidney (MDCK) type II cells were used as an in vitro model to study the regulation mechanisms of P-gp expression in the kidney under diabetic condition. P-gp protein expression was analyzed by Western blotting under the treatment of IL-6、TNF-α、insulin and glucose. Quantitative polymerase chain reaction (qPCR) was used to detect P-gp mRNA expression. In addition, the changes of intracellular ROS、PXR、CAR and ETR-A / B expressions were measured to evaluate the effect of high glucose condition on P-gp expression. In MDCK cells, P-gp protein and mRNA expression were reduced in the presence of high glucose concentration, while superoxide production was increased. After pro-inflammatory cytokines, IL-6 and TNF-α treatment, P-gp expression did not show any significantly change, as well as after insulin treatment. The reduction of P-gp expression was abolished by the treatment of an antioxidant, N-acetylcysteine (NAC). Treatment with hydrogen peroxide (H2O2) or protein kinase C (PKC) agonist, phorbol myristate acetate (PMA)significantly reduced P-gp expression. On the other hand, NAC could not reverse the reduction of P-gp expression caused by PMA treatment. However, the decrease of P-gp expression after high glucose exposure was abolished by the treatment of a PKC inhibitor, staurosporine. Furthermore, the roles of PXR, CAR and ET (Endothelin-1, ET) on P-gp regulation were investigated. The results showed that PXR and CAR mRNA expression were significantly increased under high glucose condition for 24 hours. On the other hand, PXR and CAR mRNA expression were decreased by the treatment of PKC agonist, PMA, for 12 hours. Except for PXR at 48 hours glucose treatment, in both situations, there are no significantly changes of PXR and CAR protein expression. In terms of endothelin receptor A or B (ETR-A / B), the RT-qPCR analysis did not show the mRNA expression of ETR-A / B expression in MDCK II cells. In conclusion, the expression of P-gp was decreased in MDCK II cells under high glucose condition. The regulatory pathway of P-gp expression under high glucose concentration was associated with reactive oxygen species (ROS) production and then through PKC activation. PXR / CAR, ET and ETR-A /B pathway do not play a role in this regulation. Further studies are required to understand whether there are any other factors involved in regulating P-gp. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T16:44:13Z (GMT). No. of bitstreams: 1 ntu-100-R98423006-1.pdf: 1402543 bytes, checksum: 2963f109b61a021aebfbfa8cb83a1691 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 目錄 i
表目錄 vi Abstract vii 中文摘要 x 第1章 文獻回顧 1 1.1腎臟 (Kidney) 與腎臟細胞株 1 1.1.1 腎臟簡介 1 1.1.2 體外腎臟細胞株實驗模式 1 1.2 P-glycoprotein (P-gp) 3 1.2.1 P-gp的發現與結構特徵 3 1.2.2 P-gp的分布與功能 4 1.2.3 P-gp的受質 5 1.3糖尿病 (Diabetes Mellitus) 5 1.3.1 糖尿病簡介 5 1.3.2 糖尿病實驗動物簡介 6 1.4 糖尿病腎病變 (Diabetic nephropathy) 8 1.4.1 簡介 8 1.4.2 胰島素 (insulin) 與糖尿病腎病變 9 1.4.3 發炎介質 (pro-inflammatory cytokine) 與糖尿病腎病變 10 1.4.4 高血糖 (Hyperglycemia) 與糖尿病腎病變 11 1.5活性氧化物 (Reactive oxygen species; ROS) 12 1.6蛋白激酶 C (Protein kinase C; PKC) 14 第2章 研究目的 20 第3章 實驗材料 21 3.1 MDCK II細胞培養 21 3.1.1 試劑 21 3.1.2 材料與設備 21 3.1.3緩衝液配方 21 3.2 Adult Rat Brain Endothelial Cells (ARBECs) 細胞株培養 22 3.2.1 試劑 22 3.2.2 材料與設備 22 3.3 MDCK II細胞藥物處理 23 3.3.1試劑 23 3.3.2 材料 23 3.4 MDCK II細胞膜萃取 24 3.4.1試劑 24 3.4.2材料與設備 24 3.5 蛋白質濃度測定 (Bio-Rad DC protein assay) 25 3.5.1試劑 25 3.5.2材料與設備 25 3.6 西方墨點法 (Western blot) 25 3.6.1 試劑 25 3.6.2 一級抗體 26 3.6.3 二級抗體 26 3.6.4 材料與設備 27 3.6.5緩衝液配方 27 3.7 MDCK II RNA 萃取 28 3.7.1 試劑 28 3.7.2 材料與設備 28 3.8 MDCK II RNA 反轉錄反應 28 3.8.1 試劑 28 3.8.2 材料與設備 29 3.9 定量即時聚合酶鏈鎖反應 29 3.9.1 試劑 29 3.9.2 材料與設備 29 3.10 其他儀器 29 第4章 研究方法 31 4.1 MDCK II細胞株培養 31 4.2 Adult Rat Brain Endothelial Cells (ARBECs) 細胞株培養 31 4.3 藥物處理MDCK II細胞株 31 4.4 萃取MDCK II細胞株蛋白質 32 4.4.1細胞膜蛋白萃取 (Crude membrane extraction) 32 4.4.2細胞蛋白萃取 (Cell lysate extraction) 32 4.5 蛋白質濃度測定 33 4.6 西方墨點法 (Western blot) 34 4.6.1 SDS-PAGE配置 34 4.6.2 SDS-PAGE電泳 34 4.6.3 SDS-PAGE蛋白質轉漬 34 4.6.4抗體包覆與呈色反應 35 4.7 反轉錄及定量聚合酶鏈鎖反應(RT-qPCR) 35 4.7.1 RNA 萃取 35 4.7.2反轉錄反應 (RT; reverse transcription) 36 4.7.3定量即時聚合酶鏈鎖反應 36 4.8測定超氧化物之生成 ( Measurement of superoxide production ) 37 4.9數據分析 ( Statistical analysis ) 37 第5章 實驗結果 40 5.1糖尿病影響腎臟P-gp表現量之可能因子探討 40 5.1.1發炎介質對於腎臟P-gp表現量之影響 40 5.1.2胰島素對於腎臟P-gp表現量之影響 40 5.2 MDCK II 細胞處理高濃度葡萄糖前後P-gp表現量之研究 40 5.3 MDCK II細胞內活性氧化物對於P-gp 表現變化之研究 41 5.3.1高濃度葡萄糖環境下誘導活性氧化物生成之研究 41 5.3.2 抗氧化劑NAC, PKC inhibitor STS及高濃度葡萄糖處理對於P-gp 表現影響之研究 41 5.4 MDCK II 細胞處理PKC agonist PMA前後P-gp 表現量之研究 42 5.5 MDCK II 細胞處理PKC agonist PMA及抗氧化劑NAC前後細胞膜上P-gp 表現變化之研究 42 5.6 高濃度葡萄糖對於MDCK II 細胞內PXR / CAR 表現變化之研究 43 5.7 PKC agonist PMA對MDCK II 細胞內PXR / CAR 表現變化之研究 43 5.8 高濃度葡萄糖對於MDCK II 細胞內ETR-A / B 表現變化之研究 43 第6章 結果討論 54 第7章 結論 59 第8章 參考文獻 60 | |
dc.language.iso | zh-TW | |
dc.title | 高血糖影響腎臟上皮 MDCK II細胞中 P-glycoprotein 表現之機轉探討 | zh_TW |
dc.title | Effect of hyperglycemia on P-glycoprotein expression in MDCK II cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 顧記華(Jih-Hwa Guh),許麗卿(Lih-Ching Hsu) | |
dc.subject.keyword | P-glycoprotein,高血糖, | zh_TW |
dc.subject.keyword | P-glycoprotein,hyperglycemia, | en |
dc.relation.page | 79 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.37 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。